A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers
2011

Effects of Olanzapine on Metabolism in Healthy Volunteers

Sample size: 15 publication 10 minutes Evidence: moderate

Author Information

Author(s): Vance L. Albaugh, Ravi Singareddy, David Mauger, Christopher J. Lynch

Primary Institution: The Pennsylvania State University College of Medicine

Hypothesis

Does olanzapine have acute metabolic effects in healthy volunteers similar to those observed in animal models?

Conclusion

Olanzapine administration in healthy volunteers leads to increased glucose levels and triglycerides, while decreasing free fatty acids and HDL cholesterol.

Supporting Evidence

  • Olanzapine increased glucose Area Under the Curve (AUC) by 42%.
  • Fasting plasma leptin increased by 24% after olanzapine treatment.
  • Triglycerides increased by 22% after olanzapine treatment.
  • Free fatty acids decreased by 32% after olanzapine treatment.
  • High-density lipoprotein cholesterol decreased by 10% after olanzapine treatment.

Takeaway

This study shows that taking olanzapine can change how your body processes sugar and fat, which might lead to weight gain and diabetes.

Methodology

A double blind, randomized, placebo-controlled crossover trial with healthy volunteers receiving olanzapine or placebo for three days.

Potential Biases

Potential bias due to the small, homogeneous sample of healthy volunteers may not represent the general population.

Limitations

The study was limited by a small sample size and the short duration of olanzapine exposure.

Participant Demographics

15 healthy volunteers (8 males, 7 females), aged 18-30, with BMI 18.5-25.

Statistical Information

P-Value

0.0105

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0022662

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication